BIA
ABOS icon

Bell Investment Advisors’s Acumen Pharmaceuticals ABOS Stock Holding History

Bell Investment Advisors’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-362
Closed -$620 – 1803
2025
Q3 		$620 Buy
+362
New +$501 ﹤0.01% 1695

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Bell Investment Advisors's ABOS Position: Q4 2025 in Review

Bell Investment Advisors sold out of Acumen Pharmaceuticals (ABOS) in Q4 2025, closing a stake of 362 shares — an estimated $620 sold.

Bell Investment Advisors first reported a position in ABOS in Q3 2025 and held it in 1 quarter. The position peaked at $620 in Q3 2025. 71 funds tracked by Wall St. Rank hold ABOS as of Q4 2025.

  • Bell Investment Advisors reported no remaining Acumen Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Bell Investment Advisors sold 362 Acumen Pharmaceuticals shares in Q4 2025, an estimated $620.
  • Bell Investment Advisors first reported a position in Acumen Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Bell Investment Advisors's Acumen Pharmaceuticals position peaked at $620 in Q3 2025.
  • 71 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q4 2025.

Based on Bell Investment Advisors's 13F filing for Q4 2025, filed 24 Feb 2026.